About Thomas Finn
Thomas Finn is a director at Eikonoklastes Therapeutics.
Thomas Finn first appears on SEC filings in 2021.
Experience
This experience comes from Thomas Finn's profile and from SEC filings. For roles taken from filings, the years are when the filings name Thomas Finn in the role, so the role may have started earlier or lasted longer.
AI
Auravax Therapeutics, Inc. Current
Member, Board of Directors, Auravax Therapeutics
2023 – Present
Eikonoklastes Therapeutics, Inc. Current
Member, Board of Directors
2020 – Present · Cincinnati, OH
Develops gene therapies for people with ALS and other neurodegenerative diseases.
PG
Procter & Gamble
President, Global Personal Health Care
1984 – 2020
Key Colleagues at Startups
The people Thomas Finn works with at each company, as listed on that company's latest Form D.
Eikonoklastes Therapeutics, Inc. · Form D/A, Oct 6, 2026
Bruce Halpryn
Chairman and Chief Executive Officer
SL
Samuel Lee
President and Chief Business Officer, director
KM
Kenneth Morand
Partner, CincyTech and director
RJ
Robert Johnson
CEO, Kesmalea Therapeutics and director
JN
Joseph Nolan
CEO, Jaguar Gene Therapy and director